Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023

Executive Summary

Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.

You may also be interested in...



VERIGRAFT Is Taking A Fresh Approach To Personalized Tissue Grafting

The Swedish company has developed a proprietary method of personalizing venous grafts, and plans to bring it – alongside some other products – to the market.

AI Medical Technology Doubles Down On Melanoma With Trials And Financing

Over the past month, the company has released positive clinical trial results and raised more cash, both of which will help on its way to combat melanoma.

Paragraf Is Finding A Way To Bring Graphene To Diagnostics

The UK-based company is creating a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel